Ipsen notifies availability of press release on Phase III BOLD biliary atresia trial update

PUBT · 2d ago
Ipsen notifies availability of press release on Phase III BOLD biliary atresia trial update
  • Ipsen disclosed Phase III BOLD trial of Bylvay (odevixibat) in biliary atresia missed its primary endpoint on native liver survival vs placebo.
  • Trial enrolled 254 post-Kasai patients in 19 countries; dosing was 120 mcg/kg/day for up to 104 weeks.
  • Preliminary safety data aligned with odevixibat’s established profile in approved indications.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ipsen SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607240100OMX_____CNEWS_FR_GNW1001214195_fr) on July 24, 2026, and is solely responsible for the information contained therein.